focus -WSS

focus

author：fashion 2025-09-14 18:30:16 - browse：9438

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Diverse clinical trials: Why aren’t we there yet?

focus

WSS

Regeneron agrees to White House price limits on anti

Long Covid needs a new name — and a new frame

Mega Millions pot grows to $1.25 billion after no winner

Acelyrin, a rare IPO success, stumbles in its first big test

EQRx, failed developer of low

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Wikipedia

focus

knowledge

Walensky prepares to leave CDC — and Congress — behind

FDA proposes changes to key medical devices approval pathway

Hollywood unions extend contract negotiations for actors

Hospitals consider fixing cancer drug shortages on their own

Moonlake's readout produced a cash windfall. Risks remain

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Duchenne breakthrough therapy leaves behind pioneering families

5 important ways Henrietta Lacks changed medical science

Medicare proposal to cover medical devices draws a mixed reaction

Physician groups backed by private equity giant lobby on mergers

focus

Popular nasal decongestant doesn't actually relieve congestion

Trump indictment: Who are the 'co

Walmart eyes Medicare Advantage provider ChenMed

Food makers to regulators: Ultra

WATCH: Why do bright lights make us see spots?

WATCH: Why do bright lights make us see spots?

Wikipedia

hotspot

focus

Wikipedia